IMD2128

IMD2128 is a bispecific antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR) and c-Met (hepatocyte growth factor receptor). Developed by Affinity Biopharmaceutical, it utilizes the TMEAlinker platform, which is a tumor microenvironment (TME)-activated linker specifically cleaved by extracellular legumain. The ADC carries an eribulin payload with a drug-to-antibody ratio (DAR) of 2. In preclinical studies, IMD2128 has demonstrated potent antitumor activity in lung and pancreatic carcinoma models, including those resistant to DXd-based ADCs. It exhibits high plasma stability and a favorable safety profile in non-human primates, with a highest non-severely toxic dose (HNSTD) over 16 mg/kg in cynomolgus monkeys.